Blueprint Medicines Corporation announced that Mr. Albers will transition from his current role as Chairman and President to Executive Chairman of the Board of Directors and Ms. Haviland will transition from her current role as Chief Operating Officer (COO) to President. In addition, Ms. Haviland will be appointed to serve on the company's Board of Directors, effective April 4, 2022. Christina Rossi has been promoted from Chief Commercial Officer to COO.

In her new role, Ms. Rossi will retain leadership of global commercial strategy and operations and expand her oversight to include portfolio strategy and program management, corporate development, and corporate affairs, effective April 4, 2022. Ms. Haviland joined Blueprint Medicines in January 2016 as Chief Business Officer and has served as Chief Operating Officer since January 2019.